Primary Sclerosing Cholangitis Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Primary
Sclerosing Cholangitis – Pipeline Review, H1 2019” drug
pipelines has been added to ResearchAndMarkets.com’s
offering.

Primary Sclerosing Cholangitis – Pipeline Review, H1 2019, provides
comprehensive information on the therapeutics under development for
Primary Sclerosing Cholangitis (Gastrointestinal), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide
also reviews of key players involved in therapeutic development for
Primary Sclerosing Cholangitis and features dormant and discontinued
projects. The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1,
8, 2, 11 and 1 respectively.

Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps
in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Primary
  Sclerosing Cholangitis (Gastrointestinal) by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Primary
  Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all
  their major and minor projects.
• The pipeline guide evaluates Primary Sclerosing Cholangitis
  (Gastrointestinal) therapeutics based on mechanism of action (MoA),
  drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)

Companies Mentioned

• Acorda Therapeutics Inc
• Albireo Pharma Inc
• Allergan Plc
• Conatus Pharmaceuticals Inc
• Dr. Falk Pharma GmbH
• Gilead Sciences Inc
• Intercept Pharmaceuticals Inc
• NGM Biopharmaceuticals Inc
• Nyrada Inc
• Pliant Therapeutics Inc
• Sancilio & Company Inc
• Seres Therapeutics Inc
• Shenzhen HighTide Biopharmaceutical Ltd
• Sirnaomics Inc
• Takeda Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dgoqou

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Liver
and Kidney Disorders Drugs